| Tempero’s mission is to develop next-generation therapies that selectively suppress Th17-cells and enhance specialized Treg cells. We believe that therapies that modulate only select arms of the immune response are predicted to effectively treat autoimmune disorders such as multiple sclerosis, inflammatory bowel disease, psoriasis, type 1 diabetes and rheumatoid arthritis without broadly suppressing the immune system. |
|
|
|
